[A18-20] Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V
Last updated 20.09.2018
Project no.:
A18-20
Commission:
Commission awarded on 27.03.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Haematology
Routine prophylaxis of bleeding episodes in patients with haemophilia A with factor VIII inhibitors
Added benefit not proven due to lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-26 | Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-49 | Emicizumab (haemophilia A) - Addendum to Commission A18-20 | Commission completed |
| A23-10 | Emicizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-09-20 A G-BA decision was published.